Home Newsfeeds Cowen & Co. Maintains Outperform on Varonis Systems, Lowers Price Target to $35

Cowen & Co. Maintains Outperform on Varonis Systems, Lowers Price Target to $35

Cowen & Co. analyst Shaul Eyal maintains Varonis Systems (NASDAQ:VRNS) with a Outperform and lowers the price target from $53 to $35.

byBenzinga Newsdesk

November 1, 2022

1 minute read

Cowen & Co. analyst Shaul Eyal maintains Varonis Systems (NASDAQ:VRNS) with a Outperform and lowers the price target from $53 to $35.

Global Payments Boasts ‘Best Q1 In 4 Years,’ Clocks 5% Adjusted Net Revenue Growth

By Nabaparna Bhattacharya

May 1, 10:02 AM

Global Payments Inc (NYSE: GPN) reported first-quarter FY23 adjusted net revenue growth of 5% year-on-year (+7% Y/Y at constant currency) to $2.05 billion,

GPN

Reported Late Thursday, Myriad Genetics Patient Outcomes Study Shows RiskScore Leads To More Accurate Breast Cancer Risk Prediction Than Standard-Of-Care Risk Model

By Benzinga Newsdesk

December 9, 2:40 AM

Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today presented results from a longitudinal study validating RiskScore as a well-calibrated and more accurate predictor

MYGN

Full Approval For Amgen’s Flagship Cancer Drug Lumakras Pushed For Around Four Years

By Vandana Singh

December 26, 11:45 AM

Amgen Inc (NASDAQ: AMGN) announced that the FDA has reviewed the company's supplemental New Drug Application, seeking full approval of the KRAS-blocking drug

AMGN

How To Earn $500 A Month From Chevron Stock After Q3 Earnings Report

By Lisa Levin

October 30, 8:22 AM

Chevron Corp (NYSE: CVX) reported weaker-than-expected earnings for its third quarter on Friday.

CVX

Cowen & Co. Maintains Outperform on Varonis Systems, Lowers Price Target to $35

Related Posts

Global Payments Boasts ‘Best Q1 In 4 Years,’ Clocks 5% Adjusted Net Revenue Growth

Reported Late Thursday, Myriad Genetics Patient Outcomes Study Shows RiskScore Leads To More Accurate Breast Cancer Risk Prediction Than Standard-Of-Care Risk Model

Full Approval For Amgen’s Flagship Cancer Drug Lumakras Pushed For Around Four Years

How To Earn $500 A Month From Chevron Stock After Q3 Earnings Report